Long-term trends of alanine aminotransferase levels among persons living with human immunodeficiency virus/hepatitis B virus with and without hepatitis delta coinfection.

Details

Serval ID
serval:BIB_B47685CB8341
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Long-term trends of alanine aminotransferase levels among persons living with human immunodeficiency virus/hepatitis B virus with and without hepatitis delta coinfection.
Journal
Frontiers in medicine
Author(s)
Begré L., Béguelin C., Boyd A., Peters L., Rockstroh J., Günthard H.F., Bernasconi E., Cavassini M., Lacombe K., Mocroft A., Wandeler G., Rauch A.
ISSN
2296-858X (Print)
ISSN-L
2296-858X
Publication state
Published
Issued date
2022
Peer-reviewed
Oui
Volume
9
Pages
988356
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Hepatitis delta virus (HDV) infection accelerates the progression of liver disease in persons living with HIV and hepatitis B virus (HBV) coinfection. We explored the association between HDV infection and alanine aminotransferase (ALT) elevation during tenofovir-containing antiretroviral treatment among persons living with HIV/HBV.
We included persons living with HIV/HBV with and without HDV starting tenofovir-containing antiretroviral therapy (ART) in three European cohorts with at least 18 months of follow-up. We defined HDV infection as a positive anti-HDV antibody test. We assessed risk factors for ALT elevation ≥ 1.25x upper limit of normal after 5 years of tenofovir-treatment using multivariate logistic regression models. The difference in ALT trends between individuals with and without HDV was evaluated using linear mixed effects models.
61/518 (11.8%) participants had an HDV infection. Among individuals with HDV, 63.9% had ALT elevation after 2 years and 55.6% after 5 years of tenofovir, whereas the estimates were 34.1% after two and 27.0% after 5 years in those without HDV. HDV coinfection (adjusted odds ratio 2.8, 95% confidence interval 1.4-5.8) and obesity at baseline (adjusted odds ratio 3.2, 95% confidence interval 1.2-8.0) were associated with ALT elevation after 5 years of tenofovir therapy. Mean ALT levels were consistently higher during follow-up in participants with HDV compared to those without HDV.
Persistent ALT elevation is common in persons living with HIV/HBV in Europe despite adequate HBV therapy. HDV coinfection and obesity are independent risk factors for persistent ALT elevation during long-term tenofovir treatment.
Keywords
HIV, alanine aminotransferase elevation, coinfection, hepatitis B virus, hepatitis D (delta) virus, tenofovir
Pubmed
Web of science
Open Access
Yes
Create date
11/10/2022 12:24
Last modification date
18/11/2023 7:09
Usage data